Dylan Perriseau
Dylan is a Scientist in the downstream lipid nanoparticle process. His primary role is the quality and integrity analysis of LNPs using UPLC-CAD, light scattering, and fluorescence-based techniques. He is dedicated to developing the Institute’s analytical capabilities and ensuring the quality of products provided to research and industry partners. Before joining the team in July 2023, he worked in the US research and development private sector for a decade on various therapeutic modalities in different phases of the pipeline.
Dylan’s background and industry experience incorporates cellular biology, particle analysis, oligo synthesis and formulation development. Most recent work includes an FDA approved adalimumab biosimilar and multiple successful oligonucleotide screening campaigns of extra-hepatic targets.
His hobbies include cooking, sometimes burning, a good meal and traveling with his partner.